Gain Therapeutics Inc GANX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.07
- Day Range
- $2.89–3.18
- 52-Week Range
- $2.00–5.65
- Bid/Ask
- $3.04 / $3.11
- Market Cap
- $49.15 Mil
- Volume/Avg
- 179,297 / 165,048
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 714.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.gaintherapeutics.com
Comparables
Valuation
|
Metric
|
GANX
|
PLRX
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.90 | 1.50 | 16.65 |
Price/Sales | 714.45 | 441.50 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GANX
PLRX
DYN
Financial Strength
|
Metric
|
GANX
|
PLRX
|
DYN
|
|---|---|---|---|
Quick Ratio | 3.44 | 17.43 | 2.41 |
Current Ratio | 3.59 | 17.72 | 2.53 |
Interest Coverage | — | −145.34 | — |
Quick Ratio
GANX
PLRX
DYN
Profitability
|
Metric
|
GANX
|
PLRX
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −102.15% | −22.68% | −88.69% |
Return on Equity (Normalized) | −151.44% | −24.50% | −114.25% |
Return on Invested Capital (Normalized) | −142.01% | −28.46% | −102.56% |
Return on Assets
GANX
PLRX
DYN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wdjglyvhp | Rccvk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vpxchzsz | Cznjly | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cyvcmryyv | Rfxdpzf | $97.8 Bil | |
MRNA
| Moderna Inc | Rwqpbqs | Qhmy | $41.3 Bil | |
ARGX
| argenx SE ADR | Sycnkqdkb | Mztc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gfxtnmmq | Wjg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wnjplglfn | Dhmlk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jkwhmhsj | Dcjff | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rdhkfwgb | Lzvtw | $12.5 Bil | |
INCY
| Incyte Corp | Tzddgbrd | Ptwbcvb | $11.6 Bil |